CIK 0001590560 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · fiscal year ends 12/31
| FY2025 | FY2024 | FY2017 | FY2016 | |
|---|---|---|---|---|
| Revenue (USD) | 13.1 M | 6.1 M | ||
| Diluted EPS (USD/shares) | -3.46 | -2.71 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-16 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-09-29 | 8-K | FORM 8-K items 7.01,9.01 | 2026-09-29 |
| 2026-09-02 | 8-K | 8-K items 7.01,9.01 | 2026-09-02 |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-14 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-07-29 | S-8 | S-8 | |
| 2026-07-29 | 10-Q | 10-Q | 2026-06-30 |
| 2026-07-29 | 8-K | 8-K items 2.02,9.01 | 2026-07-29 |
| 2026-07-20 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-07-16 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-07-07 | 4 | PRIMARY DOCUMENT | 2026-07-02 |
| 2026-07-02 | 4 | PRIMARY DOCUMENT | 2026-06-30 |
| 2026-07-02 | 4 | PRIMARY DOCUMENT | 2026-06-30 |
| 2026-07-02 | 144 | 144 | |
| 2026-06-30 | 4 | PRIMARY DOCUMENT | 2026-06-26 |
| 2026-06-30 | 144 | 144 | |
| 2026-06-30 | 144 | 144 | |
| 2026-06-26 | 4 | PRIMARY DOCUMENT | 2026-06-24 |
| 2026-06-26 | 144 | 144 | |
| 2026-06-25 | 144 | 144 | |
| 2026-06-24 | 8-K | FORM 8-K items 1.01,8.01,9.01 | 2026-06-23 |
| 2026-06-24 | 424B5 | 424B5 | |
| 2026-06-24 | 144 | 144 | |
| 2026-06-22 | 424B5 | 424B5 | |
| 2026-06-22 | 4 | PRIMARY DOCUMENT | 2026-06-17 |
Forms on file (last 1,000): 4 393, 8-K 154, SC 13G/A 50, 6-K 48, 144 42, 3 30, 10-Q 29, SC 13G 28. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=QURE (0.002 USD), /gw/filings/filings?ticker=QURE&form=8-K, /gw/filings/facts?ticker=QURE&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange